 Organon Co NYSE:OGN, which has recently spun-off from Merck Co., Inc. NYSE:MRK, has inherited a global business across three segments, namely Womens Health, Legacy and Biosimilars brands, according to BofA Securities. The Organon Analyst: Jason Gerberry initiated coverage of Organon with a Buy rating and a price target of 43. 